Evolus (NASDAQ:EOLS – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Evolus and TriSalus Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| TriSalus Life Sciences | 1 | 1 | 1 | 0 | 2.00 |
Evolus currently has a consensus price target of $16.00, suggesting a potential upside of 245.57%. TriSalus Life Sciences has a consensus price target of $7.00, suggesting a potential upside of 55.90%. Given Evolus’ stronger consensus rating and higher possible upside, research analysts plainly believe Evolus is more favorable than TriSalus Life Sciences.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -17.38% | N/A | -21.57% |
| TriSalus Life Sciences | -86.88% | N/A | -94.43% |
Institutional and Insider Ownership
90.7% of Evolus shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 5.9% of Evolus shares are held by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Evolus and TriSalus Life Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $297.18 million | 1.01 | -$51.64 million | ($0.81) | -5.72 |
| TriSalus Life Sciences | $45.15 million | 6.10 | -$39.23 million | ($1.83) | -2.45 |
TriSalus Life Sciences has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Evolus has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, TriSalus Life Sciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Summary
Evolus beats TriSalus Life Sciences on 9 of the 13 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
